Ignite Creation Date:
2024-05-05 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00517491
Status:
WITHDRAWN
Last Update Posted:
2019-08-05
First Post:
2007-08-16
Brief Title:
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel Somatuline ATG
Sponsor:
Ipsen
Organization:
Ipsen
Study Overview
Official Title:
A Pilot Study to Evaluate the Correlation Between Plasma Lanreotide Levels and GHIGF-1 Dynamics and Clinical Improvement in Patients With Acromegaly Treated With Lanreotide Autogel Somatuline ATG
Status:
WITHDRAWN
Status Verified Date:
2019-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Administrative reasons
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the protocol is to evaluate the correlation between plasma lanreotide levels and Growth Hormone GHInsulin Like Growth Factor 1 IGF-1 dynamics and clinical improvement in patients with acromegaly treated with lanreotide Autogel Somatuline ATG
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None